WO2004082626A3 - Aromatase inhibitor diagnosis and therapy - Google Patents

Aromatase inhibitor diagnosis and therapy Download PDF

Info

Publication number
WO2004082626A3
WO2004082626A3 PCT/US2004/008082 US2004008082W WO2004082626A3 WO 2004082626 A3 WO2004082626 A3 WO 2004082626A3 US 2004008082 W US2004008082 W US 2004008082W WO 2004082626 A3 WO2004082626 A3 WO 2004082626A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitor
liposome
implant
label
aromatase inhibitor
Prior art date
Application number
PCT/US2004/008082
Other languages
French (fr)
Other versions
WO2004082626A2 (en
Inventor
Michel Gensini
Tony Huang
Original Assignee
Ethicon Inc
Michel Gensini
Tony Huang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ethicon Inc, Michel Gensini, Tony Huang filed Critical Ethicon Inc
Priority to EP04757537A priority Critical patent/EP1603535A4/en
Publication of WO2004082626A2 publication Critical patent/WO2004082626A2/en
Publication of WO2004082626A3 publication Critical patent/WO2004082626A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1217—Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
    • A61K51/1234—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Abstract

The present invention provides pharmaceutical compositions which are useful for imaging and/or treating endometriosis. The compositions are useful for the treatment of reproductive age women, as well as post-menopausal women suffering from this disorder. The pharmaceutical composition is a liposome composition that includes a liposome carrier component that contains on its surface a moiety targeted for an endometriotic implant or leaky blood vessels within the implant. The inventive liposome composition includes an aromatase inhibitor and/or a radiolabeled complex encapsulated by the liposome component. A label capable of external detection can be included so as to permit the detection of an endometrial implant and/or diagnosis of the presence of endornetriosis in a patient. The label can be bound to the aromatase inhibitor. Alternatively, when the label is separate from the inhibitor, or when the inhibitor is not present, a radiolabeled complex can be included.
PCT/US2004/008082 2003-03-18 2004-03-17 Aromatase inhibitor diagnosis and therapy WO2004082626A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP04757537A EP1603535A4 (en) 2003-03-18 2004-03-17 Aromatase inhibitor diagnosis and therapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45551003P 2003-03-18 2003-03-18
US60/455,510 2003-03-18

Publications (2)

Publication Number Publication Date
WO2004082626A2 WO2004082626A2 (en) 2004-09-30
WO2004082626A3 true WO2004082626A3 (en) 2004-11-11

Family

ID=33030013

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/008082 WO2004082626A2 (en) 2003-03-18 2004-03-17 Aromatase inhibitor diagnosis and therapy

Country Status (2)

Country Link
EP (1) EP1603535A4 (en)
WO (1) WO2004082626A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5872466B2 (en) * 2009-07-17 2016-03-01 テクニカル ユニバーシティ オブ デンマークＴｅｃｈｎｉｃａｌ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｄｅｎｍａｒｋ Encapsulation method for producing radionuclide-containing nanoparticles
EP2651447B1 (en) 2010-12-14 2018-08-29 Technical University of Denmark Entrapment of radionuclides in nanoparticle compositions
RU2481587C1 (en) * 2012-02-21 2013-05-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт акушерства и гинекологии им. Д.О. Отта" Северо-Западного отделения Российской академии медицинских наук Method for aromatase activity test
CN102920658B (en) * 2012-11-02 2015-01-21 艾韦特(溧阳)医药科技有限公司 Liposome combined with GLP-1 (Glucagon-Like Peptide-1) analogue and polyethylene glycol and preparation method of liposome
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
US10556916B2 (en) 2014-04-01 2020-02-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Zirconium-89 oxine complex as a cell labeling agent for positron emission tomography

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5286737A (en) * 1992-05-21 1994-02-15 Kureha Kagaku Kogyo Kabushiki Kaisha Method for inhibiting aromatase
US5527528A (en) * 1989-10-20 1996-06-18 Sequus Pharmaceuticals, Inc. Solid-tumor treatment method
US6056973A (en) * 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
WO2000059547A2 (en) * 1999-04-02 2000-10-12 Center For Molecular Medicine And Immunology Method of detecting endometriosis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1173600A2 (en) * 1999-04-20 2002-01-23 The University Of British Columbia Cationic peg-lipids and methods of use
US6689387B1 (en) * 1999-09-23 2004-02-10 Bioresponse Llc Phytochemicals for treatment of mastalgia and endometriosis
CA2411542A1 (en) * 2000-06-09 2001-12-13 Teni Boulikas Encapsulation of polynucleotides and drugs into targeted liposomes
US20020177574A1 (en) * 2001-04-20 2002-11-28 Taylor Hugh S. Endometrial gene therapy
EP1390385A4 (en) * 2001-05-29 2004-11-24 Sirna Therapeutics Inc Nucleic acid based modulation of female reproductive diseases and conditions

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5527528A (en) * 1989-10-20 1996-06-18 Sequus Pharmaceuticals, Inc. Solid-tumor treatment method
US5286737A (en) * 1992-05-21 1994-02-15 Kureha Kagaku Kogyo Kabushiki Kaisha Method for inhibiting aromatase
US6056973A (en) * 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
WO2000059547A2 (en) * 1999-04-02 2000-10-12 Center For Molecular Medicine And Immunology Method of detecting endometriosis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1603535A4 *

Also Published As

Publication number Publication date
EP1603535A4 (en) 2008-10-15
WO2004082626A2 (en) 2004-09-30
EP1603535A2 (en) 2005-12-14

Similar Documents

Publication Publication Date Title
WO2004058171A3 (en) Antibodies against gpr64 and uses thereof
HK1092219A1 (en) Method for detecting neoplastic disorders in a solubilized body sample
UA101309C2 (en) Activin-actrii antagonists thereof and uses for increasing red blood cell levels
WO2003003906A3 (en) Diagnostic and screening methods for bladder cancer
SG146653A1 (en) Methods and reagents for the treatment of immunoinflammatory disorders
WO2003087831A3 (en) Proteins involved in breast cancer
WO2002085903A3 (en) Amyloid plaque aggregation inhibitors and diagnostic imaging agents
EP2196474A3 (en) Therapeutic targets in cancer
WO2002102235A3 (en) Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
WO2006063093A3 (en) Methods for diagnosis and treatment of crohn's disease
WO2006015079A3 (en) Erm family binding agents and their use in diagnosis and treatment of proliferative conditions
HUP0301877A2 (en) Aromatase inhibitors and monoclonal anti-her2 antibodies as antitumors agents
WO1999063115A3 (en) Use of cathepsin s in the diagnosis and treatment of endometriosis
MX2007003518A (en) Metalloproteinase inhibitor imaging agents.
WO2004043223A3 (en) Compositions and methods for the diagnosis and treatment of sepsis
ATE384519T1 (en) INHIBITANT AGENTS
HK1097854A1 (en) Surface-located campylobacter jejuni polypeptides
GB0124145D0 (en) Genes and proteins for prevention,prediction,prognosis and therapy of cardiovascular disease
WO2004082626A3 (en) Aromatase inhibitor diagnosis and therapy
DE60207288D1 (en) TISSUE-SPECIFIC FLUORESCENT CHELATES
IL151448A0 (en) Proteins
WO2004100998A3 (en) Compositions and methods for non-invasive imaging of soluble beta-amyloid
AU2003250190A1 (en) Combination of an aromatase inhibitor with a bisphosphonate
WO2007013124A3 (en) Stimulatory auto-antibodies to the pdgf receptor as pathology marker and therapeutic target
WO2004071273A3 (en) Method of employing elevation of marinobufagenin in determining the presence of preeclampsia and related apparatus

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2004757537

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004757537

Country of ref document: EP